Larger studies are required to evaluate the prognostic significance of sBCMA plasma levels for their potential as biomarker of response and predictor of response to BCMA-targeting therapies in relapsed multiple myeloma patients. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.